Navigation Links
DATATRAK Signs Multi-Year Agreement with Specialty Biotech

CLEVELAND, Oct. 5, 2011 /PRNewswire/ -- DATATRAK International, Inc. (OTCQX: DATA), a technology and services company focused on global eClinical solutions for the clinical trials industry, today announced the signing of a multi-year Enterprise Agreement with a specialty biologics and vaccines company.  Recognizing the value of enterprise engagements, the specialty biotech will utilize the DATATRAK ONE™ unified software suite to conduct a series of trials.

"We are pleased to add a new biotech company to our Connect Partner Program and Product Advisory Council.  Their input into the growth of our products will be invaluable," stated Laurence P. Birch, DATATRAK's Chairman of the Board and CEO. "Signing another Enterprise client demonstrates the commitment to DATATRAK's unified product suite and exemplifies the industry's need for a single solution to conducting clinical trials from Concept to Cure™."

About DATATRAK International, Inc.

DATATRAK International is a worldwide technology and services company delivering eClinical solutions and related services for the clinical trials industry. DATATRAK built its multi-component, comprehensive solution on a single, unified platform and expanded this concept to include services delivery via DATATRAK's Clinical and Consulting Services™ group. The Company delivers a complete portfolio of software products designed to accelerate the reporting of clinical research data from sites to sponsors and ultimately regulatory authorities, faster and more efficiently than loosely integrated technologies. The DATATRAK ONE™ software solution, deployed worldwide through an ASP or Enterprise Transfer offering, supports Phase I - Phase IV drug and devices studies in multiple languages throughout the world. DATATRAK has offices located in Cleveland, Ohio; Bryan, Texas; and Cary (RTP), North Carolina. For more information, visit

Except for the historical information contained in this press release, the statements made in this release are forward-looking statements. These forward-looking statements are made based on management's expectations, assumptions, estimates and current beliefs concerning the operations, future results and prospects of the Company and are subject to uncertainties and factors which are difficult to predict and, in many instances, are beyond the control of the Company, and which could cause actual results to differ materially from those contemplated in these forward-looking statements. For a list of certain of the factors that may cause actual results to differ materially from those contemplated in these forward looking statements, please see the Company's quarterly report filed with the OTCQX Market announcing its results for the three-month period ending June 30, 2011. The Company undertakes no obligation to update publicly or revise any forward-looking statement whether as a result of new information, future events or otherwise.

SOURCE DATATRAK International, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. DATATRAK International, Inc. Forms Strategic Partnership with Inclinix, Inc.
2. DATATRAK International, Inc. to Release 2009 Second Quarter and First-Half Operating Results on August 17, 2009
3. DATATRAK Signs New Client for Rescue Study
4. DATATRAK Exhibiting at the DIAs 46th Annual Meeting
5. DATATRAK Completes Sale of 357,857 Common Shares to Directors and Management
6. DAIICHI SANKYO EUROPE GmbH Selects DATATRAK eClinicalâ„¢ for Pan-European Systolic Hypertension Study
7. DATATRAK International, Inc. Announces Initial Equity Research Coverage by Zacks Investment Research
8. DATATRAK Academy Expands to Include Durham Technical Community College
9. DATATRAK Recognized as 2011 Crains Leading EDGE Award Winner
10. Research Dynamics Becomes DATATRAK Connect Partner
11. Carna Biosciences Signs Reagent Supply Agreement with Caliper Life Sciences
Post Your Comments:
(Date:11/24/2015)... - Aeterna Zentaris Inc. (NASDAQ:  AEZS) (TSX: AEZ) (the "Company"), ... Toronto Stock Exchange, confirms that as of the date ... that would cause the recent movements in the Company,s ... About Aeterna Zentaris Inc. . ... Zentaris is a specialty biopharmaceutical company engaged in developing ...
(Date:11/24/2015)... LEXINGTON, Massachusetts , November 24, 2015 ... Officer, will participate in the Piper Jaffray 27 th Annual ... on Tuesday, December 1, 2015, at 8:30 a.m. EST (1:30 p.m. ... Poulton , Chief Financial Officer, will participate in the Piper Jaffray ... City , NY on Tuesday, December 1, 2015, at 8:30 ...
(Date:11/24/2015)... ... November 24, 2015 , ... In harsh industrial ... points for in-line sensors can represent a weak spot where leaking process media ... of retractable sensor housings , which are designed to tolerate extreme process conditions. ...
(Date:11/24/2015)... HemoShear Therapeutics, LLC, a privately held ... disorders, announced today the appointment of H. ... (BOD). Mr. Watkins is the former president and ... and also served as the chairman of the ... Chairman and CEO of HemoShear Therapeutics. "The combination ...
Breaking Biology Technology:
(Date:11/12/2015)... LONDON , Nov. 11, 2015   ... and reliable analytical tools has been paving the ... and qualitative determination of discrete analytes in clinical, ... sensors are being predominantly used in medical applications, ... and environmental sectors due to continuous emphasis on ...
(Date:11/10/2015)... 2015 About signature verification ... to identify and verify the identity of an ... the secure and accurate method of authentication and ... individual because each individual,s signature is highly unique. ... dynamic signature of an individual is compared and ...
(Date:11/4/2015)... ALBANY, New York , November 4, 2015 /PRNewswire/ ... According to a new market report published by Transparency ... Size, Share, Growth, Trends and Forecast 2015 - 2022", ... value of US$ 30.3 bn by 2022. The market ... during the forecast period from 2015 to 2022. Rising ...
Breaking Biology News(10 mins):